Alejandro Villalba
Overview
Explore the profile of Alejandro Villalba including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
395
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Villalba A, Nuno L, Benito-Miguel M, Nieto-Carvalhal B, Monjo I, Novella-Navarro M, et al.
Rheumatology (Oxford)
. 2024 Aug;
PMID: 39141491
Objectives: A subset of human circulating FoxP3+ regulatory T cells expresses CD39 (cTreg39+) and hydrolyses pro-inflammatory adenine nucleotides released at inflammatory foci, rendering the anti-inflammatory agent adenosine. Methotrexate (MTX), inhibiting...
2.
Novella-Navarro M, Ruiz-Esquide V, Lopez-Juanes N, Chacur C, Monjo-Henry I, Nuno L, et al.
Clin Rheumatol
. 2024 Jul;
43(9):2817-2823.
PMID: 39009920
Objectives: To evaluate the survival of different biologic or targeted-synthetic disease-modifying antirheumatic drugs (b/tsDMARD) administered after fulfilling difficult-to-treat rheumatoid arthritis (D2TRA) criteria, and to assess factors related to treatment discontinuation....
3.
Monjo-Henry I, Uyaguari M, Nuno L, Nieto-Carvalhal B, Fernandez-Fernandez E, Peiteado D, et al.
Rheumatology (Oxford)
. 2024 Feb;
64(2):517-525.
PMID: 38321365
Objective: CD4+CXCR5+PD-1hi follicular helper T (Tfh) cells dwell in the germinal centres (GCs) of lymphoid organs and participate in RA pathogenesis. The frequency of their circulating counterparts (cTfh frequency) is...
4.
Martinez-Feito A, Novella-Navarro M, Hernandez-Breijo B, Nozal P, Peiteado D, Villalba A, et al.
Rheumatology (Oxford)
. 2024 Jan;
64(1):344-351.
PMID: 38175741
Objectives: To investigate the appearance of anti-drug antibodies (ADA) against infliximab (IFX) determined by drug-sensitive and drug-tolerant assays and their relationship with drug levels and drug survival. Methods: This longitudinal...
5.
Novella-Navarro M, Cabrera-Alarcon J, Lopez-Juanes N, Villalba A, Fernandez Fernandez E, Monjo I, et al.
RMD Open
. 2023 Sep;
9(3).
PMID: 37775112
Objectives: To analyse the trajectories of Disease Activity Score 28 (DAS28), patient global assessment (PGA) and physician global assessment (PhGA) and to assess their predictive capabilities on difficult-to-treat rheumatoid arthritis...
6.
Novella-Navarro M, Benavent D, Ruiz-Esquide V, Tornero C, Diaz-Almiron M, Chacur C, et al.
Ther Adv Musculoskelet Dis
. 2022 Oct;
14:1759720X221124028.
PMID: 36226311
Background: Despite advances in the treatment of rheumatoid arthritis (RA) and the wide range of therapies available, there is a percentage of patients whose treatment presents a challenge for clinicians...
7.
Benavent D, Franco-Gomez K, Plasencia-Rodriguez C, Novella-Navarro M, Bogas P, Nieto R, et al.
BMJ Open
. 2022 Apr;
12(4):e057850.
PMID: 35487753
Objectives: To determine the frequency of sustained remission (R) or low diseas activity (LDA) in patients with axial spondyloarthritis (axSpA) undergoing long-term biological therapy and to analyse predictive factors for...
8.
Cordero O, Vieitez I, Altabas I, Nuno-Nuno L, Villalba A, Novella-Navarro M, et al.
Arch Immunol Ther Exp (Warsz)
. 2022 Mar;
70(1):12.
PMID: 35304639
In rheumatoid arthritis (RA), the identification of biomarkers to adjust treatment intensity and to correctly diagnose the disease in early stages still constitutes a challenge and, as such, novel biomarkers...
9.
Fuentelsaz-Romero S, Barrio-Alonso C, Campos R, Torres Torresano M, Muller I, Triguero-Martinez A, et al.
Front Immunol
. 2021 Nov;
12:776879.
PMID: 34804067
The identification of "trained immunity/tolerance" in myeloid cells has changed our perception of the performance of monocytes and macrophages during inflammatory and immune responses. Pemetrexed (PMX) and methotrexate (MTX) are...
10.
Regueiro C, Nuno L, Triguero-Martinez A, Ortiz A, Villalba A, Boveda M, et al.
Sci Rep
. 2021 May;
11(1):9945.
PMID: 33976334
The initial management of rheumatoid arthritis (RA) has a high impact on disease prognosis. Therefore, we need to select the most appropriate treatment as soon as possible. This goal requires...